FDA Orange Book · active-ingredient family
Caspofungin acetate
Caspofungin acetate is approved as 2 brand and 7 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.
Reference-listed drug:CANCIDAS · NDA 021227
2
Brand (NDA)
7
Generics (ANDA)
1
Listed patents
0
Exclusivity periods
Brand (NDA) products · powder
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| CANCIDASRLD×2 | MERCK | NDA 021227 | — | Jan 26, 2001 | |
| CASPOFUNGIN ACETATE×2 | FRESENIUS KABI USA | NDA 206110 | AP | Dec 30, 2016 |
Generic (ANDA) products (7)
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| CASPOFUNGIN ACETATE×2 | HANGZHOU ZHONGMEI | ANDA 216506 | AP | Jul 18, 2025 | |
| CASPOFUNGIN ACETATE×2 | AREVA PHARMS | ANDA 211263 | AP | Oct 01, 2021 | |
| CASPOFUNGIN ACETATE×2 | CIPLA | ANDA 209489 | — | Jul 12, 2018 | |
| CASPOFUNGIN ACETATE×2 | XELLIA PHARMS APS | ANDA 205923 | — | Jul 02, 2018 | |
| CASPOFUNGIN ACETATE×2 | HENGRUI PHARMA | ANDA 200833 | — | Jun 28, 2018 | |
| CASPOFUNGIN ACETATE×2 | GLAND | ANDA 207092 | AP | Sep 29, 2017 | |
| CASPOFUNGIN ACETATE×2 | PHARMOBEDIENT | ANDA 207650 | — | Sep 29, 2017 |
Listed patents (1)
| Patent | Expires | In | Type |
|---|---|---|---|
| 9636407 | Dec 21, 2032 | in 6 yr 7 mo | Product |
Caspofungin acetate — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
